Raphael Pharmaceutical (Raphael Pharmaceutical) ROCE % : -2,668.29% (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Raphael Pharmaceutical ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Raphael Pharmaceutical's annualized ROCE % for the quarter that ended in Mar. 2024 was -2,668.29%.

Raphael Pharmaceutical ROCE % Historical Data

The historical data trend for Raphael Pharmaceutical's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Raphael Pharmaceutical ROCE % Chart

Raphael Pharmaceutical Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

ROCE %

-3,832.94

-2,835.04

-682.04

Raphael Pharmaceutical Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial									-2,127.84	-	-	-2,262.50	-2,668.29

Raphael Pharmaceutical ROCE % Calculation

Raphael Pharmaceutical's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-1.272	/	( ( (0.333 - 0.227)	+	(0.339 - 0.072) )	/ 2 )
	=	-1.272	/	( (0.106	+	0.267)	/ 2 )
	=	-1.272	/	0.1865
	=	-682.04 %

Raphael Pharmaceutical's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-2.188	/	( ( (0.339 - 0.072)	+	(0.353 - 0.456) )	/ 2 )
	=	-2.188	/	( ( 0.267	+	-0.103 )	/ 2 )
	=	-2.188	/	0.082
	=	-2,668.29 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Raphael Pharmaceutical (OTCPK:RAPH) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Raphael Pharmaceutical ROCE % Related Terms

Thank you for viewing the detailed overview of Raphael Pharmaceutical's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Raphael Pharmaceutical (Raphael Pharmaceutical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Raphael Pharmaceutical Inc (OTCPK:RAPH) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

4 Lui Paster, Tel Aviv-Jaffa, ISR, 6803605

Website

https://www.raphaelpharmaceutical.com

Raphael Pharmaceutical Inc is a pharmaceutical drug research and development company focused on the discovery and clinical development of life-improving drug therapies based on cannabinoids, including cannabidiol, or CBD oil.

Executives

Joseph Press	director	4 LUI PASTER, TEL AVIV-JAFFA L3 6803605
Shlomo Pilo	director, 10 percent owner, officer: Chief Executive Officer	4 LUI PASTER, TEL AVIV L3 6803605
Hayon Igal Louria	director, officer: Chief Technology Officer	4 LUI PASTER, TEL AVIV-JAFFA L3 6803605
Yehuda Eliya	director	4 LUI PASTER, TEL AVIV-JAFFA L3 6803605
Robert B Catell	director	62 OSBORNE ROAD, GARDEN CITY NY 11530
Elisha Yanay	director	C/O ADVANCED TECHNOLOGY ACQUISITION CORP, 14 A ACHIMEIR STREET, RAMAT GAN L3 52587
Yacov A Shamash	director
Guy Ofir	director, 10 percent owner, officer: President	40 BAZ STREET, KARMIEL L3 20100
Emanuel Cohen	director, 10 percent owner, officer: Secretary Treasurer Director	51 BILU STREET, RA'ANANA L3 00000

Raphael Pharmaceutical (Raphael Pharmaceutical) Headlines

No Headlines